NEWTOWN, Pa. – Traws Pharma, Inc. (NASDAQ: TRAW), a biopharmaceutical company focusing on antiviral therapies, has announced the retirement of its CEO, Werner Cautreels, PhD, effective at the close of business on March 31, 2025. Cautreels will continue to serve as a Board Member and transition to a special advisor role. Iain D. Dukes, D Phil, currently the Executive Board Chairman, will take over as Interim CEO. The announcement comes as the company’s stock trades at $2.40, with a market capitalization of $9.38 million. According to InvestingPro analysis, the company currently holds more cash than debt on its balance sheet.
Dr. Cautreels’ leadership saw the company through a merger and the advancement of two clinical-stage antiviral candidates targeting bird flu and COVID-19. Dr. Dukes, with extensive experience in the biopharmaceutical sector, will continue his role as Chairman while assuming CEO duties. He has held previous leadership positions at Merck Research Laboratories, Amgen, GlaxoSmithkline, and Glaxo Wellcome, and serves on several biopharma boards. The leadership transition occurs amid challenging market conditions, with the stock down 71% year-to-date, though InvestingPro data shows analysts maintain a strong buy recommendation with a $6 price target.
The company is set to discuss its pipeline progress on an Investor Update call on March 31, 2025. Traws Pharma has been developing investigational oral small molecule antivirals, including Tivoxavir marboxil for bird flu and seasonal influenza, and Ratutrelvir for COVID-19 treatment.
This leadership change comes as Traws Pharma prepares to file its Annual Report on Form 10-K with the Securities and Exchange Commission. The company’s forward-looking statements involve risks and uncertainties related to its product candidates and clinical trials. The information provided is based on a press release statement.
In other recent news, Traws Pharma, Inc. has announced significant progress in its drug development programs. The company reported promising data for its COVID-19 treatment candidate, ratutrelvir, which showed potential as a standalone therapy without the need for ritonavir. This development could simplify treatment regimens and reduce drug interaction risks. Additionally, Traws Pharma revealed positive findings for tivoxavir marboxil (TXM), a treatment for bird flu, demonstrating its efficacy in reducing lung viremia in non-human primates. The company plans to engage with the FDA to explore expedited approval pathways for both ratutrelvir and TXM.
Traws Pharma also regained compliance with Nasdaq’s stockholders’ equity requirement, following a successful equity financing round that raised $20 million. The company is now focused on advancing its antiviral drug candidates, including those targeting bird flu and seasonal influenza. While Traws Pharma’s CEO expressed gratitude for the Nasdaq Hearings Panel’s decision, the company remains under mandatory monitoring until February 2026. These developments reflect Traws Pharma’s commitment to addressing viral infections and improving patient outcomes.
